

Inventors: Huse and Glaser  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 2

81. (New) The antibody of claim 80, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

82. (New) An antibody, or functional fragment thereof, comprising a V<sub>H</sub> CDR2 selected from the group consisting of the CDRs referenced as SEQ ID NO:54, SEQ ID NO:56 and SEQ ID NO:58.

83. (New) The antibody of claim 82, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

84. (New) An antibody, or functional fragment thereof, comprising a V<sub>H</sub> CDR3 selected from the group consisting of the CDRs referenced as SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:94, SEQ ID NO:96; SEQ ID NO:98 and SEQ ID NO:100.

85. (New) The antibody of claim 84, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

86. (New) An antibody, or functional fragment thereof, comprising a V<sub>L</sub> CDR1 referenced as SEQ ID NO:82.

B1  
Cont.

Inventors: Huse and Glaser  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 3

87. (New) The antibody of claim 86, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

88. (New) An antibody, or functional fragment thereof, comprising a V<sub>L</sub> CDR2 referenced as SEQ ID NO:84.

89. (New) The antibody of claim 88, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

90. (New) An antibody, or functional fragment thereof, comprising a V<sub>L</sub> CDR3 selected from the group consisting of the CDRs referenced as SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90 and SEQ ID NO:92.

B1  
Cont.  
91. (New) The antibody of claim 90, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

92. (New) An antibody, or functional fragment thereof, comprising the combination of CDRs selected from the group consisting of:

the V<sub>L</sub> CDR1 referenced as SEQ ID NO:82 and the V<sub>H</sub> CDR3 referenced as SEQ ID NO:68;

the V<sub>L</sub> CDR1 referenced as SEQ ID NO:82, the V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and the V<sub>H</sub> CDR3 referenced as SEQ ID NO:68;

Inventors: Huse and Glaser  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 4

the V<sub>L</sub> CDR1 referenced as SEQ ID NO:82, the V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and the V<sub>H</sub> CDR3 referenced as SEQ ID NO:72;

the V<sub>L</sub> CDR1 referenced as SEQ ID NO:82, the V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and the V<sub>H</sub> CDR3 referenced as SEQ ID NO:70;

the V<sub>L</sub> CDR1 referenced as SEQ ID NO:82 and the V<sub>H</sub> CDR3 referenced as SEQ ID NO:72;

the V<sub>L</sub> CDR3 referenced as SEQ ID NO:86, the V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and the V<sub>H</sub> CDR3 referenced as SEQ ID NO:68;

the V<sub>L</sub> CDR3 referenced as SEQ ID NO:90 and V<sub>H</sub> CDR3 referenced as SEQ ID NO:68; and

the V<sub>L</sub> CDR3 referenced as SEQ ID NO:90, the V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and V<sub>H</sub> CDR3 referenced as SEQ ID NO:68.

B1  
cont.  
93. (New) The antibody of claims 92, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

94. (New) An antibody, or functional fragment thereof, comprising the combination of CDRs selected from the group consisting of:

the V<sub>L</sub> CDR1 referenced as SEQ ID NO:82, the V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and the V<sub>H</sub> CDR3 referenced as SEQ ID NO:94;

Inventors: Huse and Glaser  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 5

the V<sub>L</sub> CDR3 referenced as SEQ ID NO:90, the V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and the V<sub>H</sub> CDR3 referenced as SEQ ID NO:94;

the V<sub>L</sub> CDR3 referenced as SEQ ID NO:90, the V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and the V<sub>H</sub> CDR3 referenced as SEQ ID NO:96;

the V<sub>L</sub> CDR3 referenced as SEQ ID NO:90 and the V<sub>H</sub> CDR3 referenced as SEQ ID NO:94;

the V<sub>L</sub> CDR3 referenced as SEQ ID NO:90 and the V<sub>H</sub> CDR3 referenced as SEQ ID NO:98; and

the V<sub>L</sub> CDR3 referenced as SEQ ID NO:90, the V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and the V<sub>H</sub> CDR3 referenced as SEQ ID NO:100.

95. (New) The antibody of claims 94, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

96. (New) An antibody, or functional fragment thereof, comprising the combination of CDRs selected from the group consisting of:

the V<sub>L</sub> CDR1 referenced as SEQ ID NO:82 and the V<sub>H</sub> CDR3 referenced as SEQ ID NO:68;

the V<sub>L</sub> CDR1 referenced as SEQ ID NO:82, the V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and the V<sub>H</sub> CDR3 referenced as SEQ ID NO:68;

31  
Cont.

Inventors: Huse and Glaser  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 6

the  $V_L$  CDR1 referenced as SEQ ID NO:82, the  $V_H$  CDR2 referenced as SEQ ID NO:56 and the  $V_H$  CDR3 referenced as SEQ ID NO:72;

the  $V_L$  CDR1 referenced as SEQ ID NO:82, the  $V_H$  CDR2 referenced as SEQ ID NO:56 and the  $V_H$  CDR3 referenced as SEQ ID NO:70;

the  $V_L$  CDR1 referenced as SEQ ID NO:82 and the  $V_H$  CDR3 referenced as SEQ ID NO:72;

the  $V_L$  CDR3 referenced as SEQ ID NO:86, the  $V_H$  CDR2 referenced as SEQ ID NO:56 and the  $V_H$  CDR3 referenced as SEQ ID NO:68;

the  $V_L$  CDR3 referenced as SEQ ID NO:90, the  $V_H$  CDR2 referenced as SEQ ID NO:56 and the  $V_H$  CDR3 referenced as SEQ ID NO:94;

the  $V_L$  CDR3 referenced as SEQ ID NO:90 and  $V_H$  CDR3 referenced as SEQ ID NO:68;

the  $V_L$  CDR3 referenced as SEQ ID NO:90, the  $V_H$  CDR2 referenced as SEQ ID NO:56 and  $V_H$  CDR3 referenced as SEQ ID NO:68;

the  $V_L$  CDR1 referenced as SEQ ID NO:82, the  $V_H$  CDR2 referenced as SEQ ID NO:56 and the  $V_H$  CDR3 referenced as SEQ ID NO:94;

the  $V_L$  CDR3 referenced as SEQ ID NO:90, the  $V_H$  CDR2 referenced as SEQ ID NO:56 and the  $V_H$  CDR3 referenced as SEQ ID NO:96;

the  $V_L$  CDR3 referenced as SEQ ID NO:90 and the  $V_H$  CDR3 referenced as SEQ ID NO:94;

the  $V_L$  CDR3 referenced as SEQ ID NO:90 and the  $V_H$  CDR3 referenced as SEQ ID NO:98; and

B  
cont.

Inventors: Huse and Glaser  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 7

the  $V_L$  CDR3 referenced as SEQ ID NO:90, the  $V_H$  CDR2 referenced as SEQ ID NO:56 and the  $V_H$  CDR3 referenced as SEQ ID NO:100.

97. (New) The antibody of claim 96, wherein said functional fragment is selected from the group consisting of Fv, Fab,  $F(ab)_2$  and scFV.

98. (New) A method of inhibiting a function of  $\alpha_v\beta_3$  comprising contacting  $\alpha_v\beta_3$  with the enhanced LM609 grafted antibody of claim 56, or a functional fragment thereof, under conditions which allow binding of said enhanced LM609 grafted antibody to  $\alpha_v\beta_3$ .

99. (New) The method of claim 98, wherein said functional fragment is selected from the group consisting of Fv, Fab,  $F(ab)_2$  and scFV.

100. (New) The method of claim 98, wherein said function of  $\alpha_v\beta_3$  is binding of  $\alpha_v\beta_3$  to a ligand.

101. (New) The method of claim 98, wherein said function of  $\alpha_v\beta_3$  is integrin mediated signal transduction.

102. (New) A method of treating an  $\alpha_v\beta_3$ -mediated disease comprising administering an effective amount of the enhanced LM609 grafted antibody of claim 56, or a functional fragment thereof, under conditions which allow binding to  $\alpha_v\beta_3$ .

B1  
Cont.